# Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

> **NCT00910897** · PHASE3 · UNKNOWN · sponsor: **Intergroupe Francophone du Myelome** · enrollment: 205 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade-Dexamethasone
- **DRUG:** Velcade-Thalidomide-Dexamethasone

## Key facts

- **NCT ID:** NCT00910897
- **Lead sponsor:** Intergroupe Francophone du Myelome
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2009-08
- **Final completion:** —
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2009-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910897, "Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00910897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*